NYSE:ABBVAbbVie Stock Price, Forecast & News

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABBV shares have increased by 14.1% and is now trading at $96.83. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AbbVie.

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 31st 2020. View our earnings forecast for AbbVie.

AbbVie will be holding an earnings conference call on Friday, July 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AbbVie Inc (NYSE:ABBV) issued its earnings results on Friday, May, 1st. The company reported $2.42 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.25 by $0.17. The firm earned $8.62 billion during the quarter, compared to analyst estimates of $8.31 billion. AbbVie had a negative return on equity of 169.80% and a net margin of 24.77%. The business's quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.14 EPS. View AbbVie's earnings history.

AbbVie announced a quarterly dividend on Wednesday, June 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $1.18 per share on Friday, August 14th. This represents a $4.72 dividend on an annualized basis and a yield of 4.87%. The ex-dividend date of this dividend is Tuesday, July 14th. View AbbVie's dividend history.

AbbVie announced that its board has approved a share buyback plan on Thursday, December 13th 2018, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 3.8% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board believes its stock is undervalued.

AbbVie issued an update on its FY 2020 After-Hours earnings guidance on Friday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $50-50 billion.

17 Wall Street analysts have issued twelve-month price objectives for AbbVie's stock. Their forecasts range from $90.00 to $125.00. On average, they expect AbbVie's share price to reach $106.80 in the next year. This suggests a possible upside of 10.3% from the stock's current price. View analysts' price targets for AbbVie.

News coverage about ABBV stock has been trending negative this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AbbVie earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news about AbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Bristol-Myers Squibb (BMY) and Valeant Pharmaceuticals Intl (VRX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.15%), DNB Asset Management AS (0.07%), Manning & Napier Group LLC (0.03%), State of Alaska Department of Revenue (0.02%), Vigilant Capital Management LLC (0.02%) and Park National Corp OH (0.01%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including 6 Meridian, Municipal Employees Retirement System of Michigan, HNP Capital LLC, Park National Corp OH, Exane Derivatives, Gradient Investments LLC, Richard P Slaughter Associates Inc, and First National Bank of Mount Dora Trust Investment Services. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Jeffrey Ryan Stewart, and Timothy J Richmond. View insider buying and selling activity for AbbVie.

ABBV stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Envestnet Asset Management Inc., State of Alaska Department of Revenue, Contravisory Investment Management Inc., Mountain Capital Investment Advisors Inc, Canandaigua National Corp, Moody National Bank Trust Division, and Whittier Trust Co.. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $96.83.

AbbVie has a market capitalization of $142.99 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

The official website for AbbVie is www.abbvie.com.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.